Palmar-Plantar Erythrodysesthesia Syndrome Clinical Trial
Official title:
A Phase II Placebo Controlled, Multicenter Study to Investigate the Safety and Efficacy of ATH008 Cream in Patients With Palmar-Plantar Erythrodysesthesia Syndrome (PPES) Secondary to Capecitabine Therapy.
The aim of this study is to evaluate the safety and efficacy of ATH008 cream in patients with Palmar-Plantar Erythrodysesthesia Syndrome (PPES) secondary to capecitabine therapy. In part I, the safety and plasmatic levels of the active ingredient and its metabolite will allow to determine the most appropriate and beneficial dose for the second part of the study. In Part II, the efficacy of ATH008 cream in reducing the number of patients presenting PPES grade 2/3 secondary to capecitabine therapy following a four times daily application will be tested.
| Status | Completed |
| Enrollment | 122 |
| Est. completion date | August 2013 |
| Est. primary completion date | August 2013 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Are under capecitabine monotherapy for treatment of colon or breast cancer at a regimen of 2 weeks on and 1 week off (14+7) and a daily doses between 2000 and 2500 mg/m2. - Diagnosis of PPES grade 1 in any hand or foot according to the NCI CTCAE v4.03 definition. - In Part I, subjects still have to undergo at least 1 planned cycle with capecitabine monotherapy. - In Part II, subjects still have to undergo at least 2 planned cycles with capecitabine monotherapy. Exclusion Criteria: - Are younger than 18 years. - Use of other chemotherapies for the treatment of cancer except trastuzumab (Herceptin®) or bevacizumab (Avastin®). - Diagnosis of PPES grade 1 in any hand or foot according to the NCI CTCAE v4.03 definition for more than 2 cycles previously to inclusion in this clinical study. - Have neurologic symptoms greater than grade 1, which under the criteria of the clinician could interfere with PPES diagnosis or study treatment (e.g. hands or feet neuropathy). - Have any dermatologic condition that in the opinion of the investigator may affect hands or feet or may complicate evaluation during study treatment (e.g. neurodermatitis, psoriasis, etc). - Have onycholysis with a non-stable grade 1 or onycholysis greater than grade 1 (nail loss, NCI CTCAE v4.03 criteria) which in the assessment of the clinician could interfere with PPES diagnosis or study treatment. - Need to use other emollient creams or other topical treatments in hands and/or feet during the study. - Are receiving radiotherapy. - Have received topical corticosteroids in hands or feet 7 days prior to planned inclusion in the study. - Are participating in any other investigational studies for the treatment of PPES. - Have participated in any other investigational studies for the treatment of PPES, or received an experimental therapeutic procedure, considered to potentially interfere with the study in the 4 weeks preceding Day 1. The above is not a complete list of eligibility criteria. Please see your study doctor for more information. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| Belgium | Imelda | Bonheiden | |
| Belgium | Institute Jules Bordet | Brussels | |
| Belgium | AZ Maria Middelares | St-Niklaas | |
| Germany | Iniversitätsklinikum Hamburg Eppendorf | Hamburg | |
| Germany | OncoResearch Lerchenfeld UG | Hamburg | |
| Germany | Klinikum Offenbach GmbH | Offenbach | |
| Germany | Prosper Hospital | Recklinghausen | |
| Italy | A.O. Universitaria Policlinico S.Orsola-Malpighi di Bologna | Bologna | |
| Italy | IRCCS - Istituto Europeo di Oncologia (IEO) di Milano | Milano | Dr. Franco Nolè |
| Italy | Azienda Ospedaliero Universitaria "Maggiore Della Carità" di Novara | Novara | |
| Italy | Azienda Ospedaliero Universitaria di Sassari | Sassari | |
| Spain | HGU Alicante | Alicante | |
| Spain | Hospital del Mar | Barcelona | |
| Spain | Hospital Vall d'Hebron | Barcelona | |
| Spain | Complejo Hospitalario Regional Reina Sofia | Córdoba | |
| Spain | Hospital General de Elche | Elche | |
| Spain | Institut Català d'Oncología | L'Hospitalet de Llobregat | Barcelona |
| Spain | HGU La Paz | Madrid | |
| Spain | Hospital Clínic i Provincial | Madrid | |
| Spain | Hospital Gregorio Marañón | Madrid | |
| Spain | Hospital Ramón y Cajal | Madrid | |
| Spain | Hospital Puerta de Hierro | Majadahonda | Madrid |
| Spain | Hospital de Navarra | Pamplona | |
| Spain | Hospital de Torrevieja | Torrevieja | |
| Spain | Institut Valencià d'Oncologia | Valencia | |
| Spain | Hospital Miguel Servet | Zaragoza |
| Lead Sponsor | Collaborator |
|---|---|
| Advancell - Advanced In Vitro Cell Technologies, S.A. | Cromsource |
Belgium, Germany, Italy, Spain,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Efficacy of ATH008 cream in reducing the number of subjects presenting PPES grade 2/3 secondary to capecitabine therapy | percentage of subjects that develop PPES grade 2 or 3 according to the NCI CTCAE v4.03 criteria | minimum every 21 days, maximum of 4 capecitabine cycles, followed by a safety observation period of 14 days | No |
| Primary | Safety of ATH008 cream in patients presenting PPES secondary to capecitabine therapy | adverse events and serious adverse events (incidence, causality, and severity) related to treatment with ATH008 cream | minimum every 21 days, maximum of 4 capecitabine cycles, followed by a safety observation period of 14 days | Yes |
| Primary | Plasmatic levels of ATH008 cream when given topically | plasmatic levels of the active ingredient and its metabolite when given topically | blood sampling at specific timepoints (Pre-dose, Day 1 and Day 21) | Yes |
| Secondary | Efficacy of ATH008 cream in improving the quality of life of patients presenting PPES | quality of life compared to baseline | minimum every 21 days, maximum of 4 capecitabine cycles, followed by a safety observation period of 14 days | No |
| Secondary | Efficacy of ATH008 cream in improving signs and symptoms of PPES | proportion of subjects that present no PPES signs or symptoms, time to progression and time to improvement of PPES grades,assessment from photographs of erythema, desquamation, existence of blisters, fissures and ulcers; percentage of palms and soles affected by PPES | minimum every 21 days, maximum of 4 capecitabine cycles, followed by a safety observation period of 14 days | No |
| Secondary | Assessment of patient reported pain | assessment of pain, using a 0-10 score, analysed comparing the values measured during the study treatment period with the baseline pain value | minimum every 21 days, maximum of 4 capecitabine cycles, followed by a safety observation period of 14 days | No |
| Secondary | Accumulated dose intensity of capecitabine before and during ATH008 cream treatment | accumulated capecitabine dose during study treatment (mg / m2) from the starting of ATH008 cream treatment | minimum every 21 days, maximum of 4 capecitabine cycles, followed by a safety observation period of 14 days | No |